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models. ConClusions: The specified mapping algorithms from the BDI index to 
the EQ-5D-3L index for patients with depressive disorders are acceptable for usage 
as approximation in cost-utility analyses. A further validation in independent sam-
ples is necessary to obtain more confidence in their performance.
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objeCtives: LPLD is an ultra-orphan genetic lipid disorder (prevalence 1-2/mil-
lion). It is associated with severe hypertriglyceridemia and an increased risk of 
acute pancreatitis. Other manifestations include eruptive xanthoma, fatigue, dif-
ficulty with concentrating and cardiopulmonary symptoms. Associated symptoms, 
complications and the fat-restricted diet affect Quality of Life (QOL). Currently no 
disease-specific measure exists to assess QOL and the burden of LPLD. As part of 
post approval commitments of alipogene tiparvovec, regulatory bodies requested 
the development of a reliable measure of QOL in LPLD. This study evaluates exist-
ing EORTC questionnaires QLQ-C30 and QLQ-PAN26, and a new questionnaire of 
disease burden devised by clinicians with experience in treating LPLD. Methods: 
To date, eight genetically confirmed LPLD-patients from four countries assessed 
the relevance and importance of each item of the three questionnaires. Patients’ 
ratings were discussed during an in-depth, face-to-face interview and the dis-
ease burden questionnaire was comprehensively discussed, analyzed and then 
modified where necessary. Results: Quantitative assessment showed that 25 
(45%) of the QLQ-C30 and QLQ-PAN26 questions were relevant to the majority of 
patients. The most relevant items were pain (6), fatigue and sleeping problems 
(4), digestive and dietary factors (4), work, daily and social activity restrictions (4) 
and impact on emotional functioning (3). Qualitative and quantitative analysis 
of the new questionnaire highlighted the unpredictability of pancreatitis attacks 
and the impact of the strict low fat diet on social and emotional factors. Less 
common clinical manifestations of LPLD (xanthoma, dyspnea) were very impor-
tant to those affected. The new questionnaire has been modified and items on 
alcohol use and painkillers added for ongoing evaluation. ConClusions: Five 
QOL domains relevant to LPLD have been identified using existing questionnaires. 
A new disease-specific questionnaire identifies significant impacts on patients’ 
lives. These instruments may help clinicians to effectively use pharmacological 
and genetic therapy to manage LPLD patients.
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objeCtives: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is 
one of the most widely used health-related quality of life (HRQoL) specific ques-
tionnaires for patients with heart failure (HF). It provides two dimensions (physical 
and emotional) and a global score. However, there are some concerns about its 
factor structure, and different alternatives have been proposed, including even a 
third factor representing a social dimension. The objective of the present study 
was to study the internal structure of the MLHFQ, the unidimensionality of the 
total score, and to compare the different factor structures raised. Methods: We 
included 2565 patients hospitalized for HF, who were provided with the MLHFQ 
during hospitalization. The structural validity of the questionnaire was studied 
by confirmatory factor analysis (CFA) for categorical data, and the Rasch rating 
scale model. These two approaches were also applied to the different structures 
proposed. Results: The results of the CFA for the hypothesized model of two 
latent factors and the Rasch analysis confirmed the adequacy of the physical and 
emotional dimensions. We only found two problematic items within the total 
score. The results of the CFA applied to other two-factor structures proposed were 
not better than the results of the original structure. The Rasch analysis applied 
to the different social factors showed the best results for Munyombwe’s social 
dimension. ConClusions: The results support the validity of using the MLHFQ 
physical and emotional subscales in patients with HF, as well as the total score. 
In addition, the results confirmed the existence of a third social factor, and we 
recommend the use of Munyombwe’s social factor.
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last-visit versions, whilst other items should be scored individually. The last-visit 
version discriminates treatment response.
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objeCtives: In recent years, the healthcare industry has witnessed a trend for regula-
tory approvals of innovative technologies in oncology without head-to-head clinical 
trial evidence or Health Related Quality-of-Life (HRQoL) data. This yields a challenge 
to decision-makers who require a cost-effectiveness analysis (CEA) to conduct Health 
Technology Assessments. To demonstrate methodological approaches and potential 
data sources to address these gaps, we present a case study using recently approved 
drugs lenvatinib and sorafenib for management of radioiodine-refractory differenti-
ated thyroid cancer (RR-DTC). Methods: A vignette study was conducted to elicit 
utilities for RR-DTC health-states and estimate the impact of toxicities on HRQoL. 
Phase III clinical trial data with crossover correction were used to compare clinical-
endpoints of Progression Free Survival (PFS) and Overall Survival (OS) for both len-
vatinib and sorafenib. Adjustments for study population differences were addressed 
using Matching-Adjusted Indirect Comparison. PFS and OS data were extrapolated 
to 10 years using proportional hazard, accelerated time failure, individual parametric 
models and piecewise models and time in health states was estimated from the 
partitioning of survival time into pre- and post-progression. Results: Adjusted 
HRs for lenvatinib vs. sorafenib were estimated as 0.37(95%CI: 0.25-0.55) for PFS and 
0.79(0.45-1.37) for OS. PFS (stable) health-state utilities for each drug were adjusted 
using tumor response rates and incremental utility gain. Combining phase III toxicity 
rates with utility decrements yielded a total disutility of 0.042 for lenvatinib vs. 0.117 
for sorafenib. Survival extrapolation (undiscounted) provided estimates of incremen-
tal 0.66 LYS and 0.60 QALY for lenvatinib vs. sorafenib. ConClusions: This analysis 
demonstrated that in absence of head-to-head trials and QoL trial data, vignette utility 
studies and ITC may be used to aid with QALY analysis, especially in orphan diseases 
where limited data are available. Vignette studies and ITC can increase reliability of 
comparative-effectiveness data and support payers’ decision making.
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objeCtives: Lack of rigour in PRO data analysis leads to uncertainty around the 
quality of results impacting the extent to which conclusions can be drawn from 
the data. This study sought to provide guidelines for PRO efficacy data analysis for 
study sponsors in order to ensure confidence in PRO results by stakeholder decision 
makers. Methods: A targeted review was undertaken of guidelines for clinical 
trial and PRO data analysis, and published PRO analysis studies that demonstrated 
good practice in PRO efficacy analysis. The evidence was synthesised by a team 
comprising statistical and PRO experts experienced in the analysis of PRO efficacy 
data. An 8-step guideline was developed based on the available evidence. Results: 
Eight steps that will ensure high quality analysis of PRO trial efficacy data are (1) 
avoid unplanned or post analysis by developing a PRO specific SAP prior to data 
base lock, or document comprehensive PRO data analysis in the clinical trial SAP 
(2) ensure awareness of differing requirements across stakeholders in PRO data 
analysis/interpretation and adequately address this in the SAP to ensure (3) specify 
primary and secondary PRO endpoints and/or approaches to correcting for multi-
plicity (4) develop and specify appropriate approaches to handling missing data 
including sensitivity analysis (5) include analysis of PRO score change from base-
line (6) specify approaches to interpreting change from baseline data including 
any benchmarks which will be applied during interpretation (7) implement a 100% 
double programming approach alongside table review by statistically qualified team 
members (8) interpret PRO results not only in isolation but alongside other clini-
cal outcomes ConClusions: For PRO data to effectively inform decision making 
across all stakeholders, high standards of data analysis needs to be mandatory. This 
8-step guideline, if adhered to, will raise the standard of PRO data analysis reducing 
the likelihood that PRO data is discounted by decision makers.
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objeCtives: For cost-utility analyses, data on health state utilities, as provided by 
the EQ-5D-3L, is needed but not always available. This study specifies a mapping 
algorithm from the Beck Depression Inventory (BDI) index to the EQ-5D-3L index 
adjusted for specific socio-demographic variables for patients with depressive dis-
orders. Methods: A sample of 1,074 consecutive patients with depressive disorders 
from a psychotherapeutic outpatient clinic was included in the study. Standardized 
clinical interviews were applied to establish reliable diagnoses. For the prediction 
of the EQ-5D-3L index from the BDI index and selected patient socio-demographic 
characteristics, ordinary least squares regression with robust standard errors was 
used. Model prediction properties were tested using the root mean squared error 
and repeated random sub-sampling cross-validation. Results: The BDI index 
predicted the EQ-5D-3L index with a significant proportion of variance explained. 
The highest model goodness of fit was estimated for models with the BDI index 
and age as independent variables. The root mean squared error of the predicted 
EQ-5D-3L index in the validation samples ranged from 0.225 to 0.228 between the 
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principal components analysis and descending hierarchical classification. Results: 
Steps 1–3: Development and adaptation of a self-reported 44-item questionnaire on 
a 0–10 scale of fears and beliefs. 5 domains established a priori: origin of the disease, 
flares, treatments, disease progression and consequences of disease. Step 4: In the 
study of 226 patients (161 RA, 65 axSpA), all dimensions were ≥ 0.79 and ≤ 0.93, apart 
from the domain “origin of the disease” (0.67). Principal component analysis identi-
fied 6 axes (63.7% of variance explained) and the descending hierarchical analysis 
identified 9 clusters (63.7% of variance). 2 clusters were highly correlated (r2= 0.80) 
and combined into a single cluster. Based on the psychometric validation, the fol-
lowing domains were identified: fears of the disease progression/consequences (18 
items) and fears about treatment (5); beliefs related to: psychological influence (2), 
genetic influence (2), physical influence (4), diet influence (4), lifestyle (3) and diverse 
opinions (4). ConClusions: This analysis confirms the internal consistency of the 
questionnaire developed. The scoring results should help physicians to understand 
their patients’ perceptions of their disease better and eventually lead to improved 
adherence to treatment.
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objeCtives: Measuring poverty in health care settings may contribute to identifying 
patients in poverty and subsequently getting appropriate management. Although 
many scales are available to measure poverty in health, less attention has been paid 
to the poverty related quality of life. The purpose of this methodological study was to 
adapt the Poverty Related Quality of Life Questionnaire developed by Boyer and others 
(2014) into Turkish and to evaluate its psychometric properties for a Turkish patient 
population. Methods: The scale was adapted into Turkish through a translation and 
back-translation process. The content validity of the scale was assessed using expert 
approval. The psychometric properties of the scale were investigated by collecting 
data from 300 patients in 3 emergency departments from random selected hospitals 
in Ankara during the period of 1 April–30 May 2015. Results: An exploratory factor 
analysis identified that the seven-factor structure accounted for 80.1% of the total 
variance. A confirmatory factor analysis indicated a sufficient model fit for the con-
struct validity of the scale: root mean square error of approximation, 0.041; compara-
tive fit index, 0.93; general fit index, 0.97; standardized root mean square residual, 
0.050. Cronbach’s alpha for the total scale was 0.83 and each item achieved the 0.40 
standard for item internal consistency. Significant associations with socioeconomic 
and clinical indicators showed good discriminant validity. ConClusions: This study 
supports the validity and reliability of the Turkish version of Poverty Related Quality 
of Life Questionnaire. This instrument can be used to measure multiple aspects of 
poverty in the health care settings; however, as poverty and quality of life are con-
textual facts, further work is needed to test the psychometric properties of this scale 
both in Turkish and different cultures.
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objeCtives: The objective of this study was to develop and validate a decision algo-
rithm that replicates expert opinion regarding the level of disease activity in patients 
with acromegaly. Methods: A panel of key experts in endocrinology and outcomes 
research provided input as to what parameters are critical to assess disease activity. 
The top five parameters where then subsequently defined at three levels of severity. 
A final set of 243 unique health states were developed. A group of 21 expert endo-
crinologists from 5 European countries and Canada was recruited to participate 
in a discrete choice experiment. Each participant was presented with 10 common 
scenarios and 42 additional scenarios selected at random and asked to indicate 
whether the hypothetical patient was stable, having mild disease activity needing 
further evaluation, or having significant disease activity requiring clinical action. 
Concordance in decisions based on the 10 common scenarios was tested using Fleiss 
Kappa and a set of linear prediction models tested to predict outcome. Results: 
The five parameters included: 1) IGF-I level (SDS score); 2) tumor status (change 
on MRI); 3) comorbidities (number and severity); 4) signs and symptoms (Patient 
Acromegaly Symptom Questionnaire score); and 5) health-related quality of life 
(scored on a disease specific measure). The Inter-rater reliability was adequate 
(Kappa = 0.52). Based on a CART analysis, the decision model of best fit was dis-
junctive with IGF-1 and Tumor status primarily predicting the health status. The 
remaining three parameters were instructive but not deterministic. ConClusions: 
Biochemical and tumor status are the primary predictors of disease activity, with 
the patient’s perceived disease state playing a secondary role. This may highlight 
the need for a more patient-centered approach to acromegaly disease manage-
ment. To enable clinical use of the model, a disease specific tool named ACRODAT 
(ACROmegaly Disease Activity Tool) is currently in further development.
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objeCtives: To assess effects of CZP+MTX vs placebo (PBO)+MTX on patient 
reported outcomes in DMARD-naïve patients with severe, active and progressive 
RA. Methods: Patients in this double-blind randomized study (NCT01519791) 
were DMARD-naïve with active RA< 1yr diagnosis at baseline (BL), fulfilling 
2010 ACR/EULAR criteria; ≥ 4 swollen and ≥ 4 tender joints; DAS28[ESR]≥ 3.2; 
CRP≥ 10mg/L and/or ESR≥ 28mm/hr, rheumatoid factor/ACPA positive. Patients 
were randomized 3:1 to CZP (400mg Wks 0,2,4 then 200mg Q2W to Wk52)+MTX 
or PBO+MTX. MTX was initiated at 10mg/wk, increased up to 25mg/wk by Wk8, 
maximum tolerated dose maintained to Wk52. HAQ-DI, PtGADA, Pain VAS, %pts 
achieving normative physical function (HAQ-DI≤ 0.5), health-related QoL (SF-36, 
EQ-5D-3L) were assessed. At Wk52 changes from baseline (CFB) were analyzed 
using ANCOVA (LOCF imputation); categorical variables were analyzed using 
logistic regression (non-responder imputation). Data are LS mean CFB (SE) unless 
otherwise specified. Results: 660 (CZP+MTX) and 219 (PBO+MTX) patients were 
randomized; 655 vs 213 in the full analysis set (patients with baseline and post-
baselineL DAS28[ESR]). Baseline characteristics were balanced between study 
arms; mean (SD) HAQ-DI= 1.6 (0.6), Pain VAS= 66.1 (22.4), PtGADA= 65.3 (22.0). 
At Wk52, greater improvements from baseline were observed with CZP+MTX 
vs PBO+MTX in HAQ-DI (-1.0 [0.0] vs -0.8 [0.0], p< 0.001; 48.1% vs 35.7% patients 
reached normative function), pain (-48.5 [1.0] vs -44.0 [1.7], p< 0.05), PtGADA (-46.7 
[1.0] vs -42.0 [12.5], p< 0.05) and health-related QoL measured by SF-36 (physical 
component summary score= 12.4 [0.4] vs 10.7 [0.6], p< 0.01; mental component 
summary score= 8.2 [0.5] vs 6.8 [0.7]). Numerically higher proportions of CZP+MTX 
patients reported no problems in domains of the EQ-5D-3L vs PBO+MTX patients, 
including mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion. ConClusions: In DMARD-naïve patients with severe, active and progressive 
RA, CZP+MTX showed greater improvements at 1-year in physical function, pain, 
disease activity and health-related QoL compared to PBO+MTX.
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objeCtives: To carry-out the cultural adaptation into Spanish (for Spain) of the 
questionnaire “Overactive Bladder - Family Impact Measure (OAB-FIM)”. Methods: 
The adaptation included linguistic validation through forward and back transla-
tions in duplicate, reviewed by a panel experts and a debriefing with relatives of 
OAB patients, and a phase of preliminary measurement of psychometric proper-
ties in OAB patients and their relatives of habitual coexistence, of both genders, 
≥ 18 years of age, newly diagnosed and on-therapy for their symptoms of OAB. 
Conceptual and linguistic equivalences, internal consistency (α -Cronbach), con-
tent validity (the inter-rater Rovinelli-Hambleton index of item congruence) and 
construct validity were measured. Construct validity included concurrent validity 
(with scales ZARIT and OABq-SF), and validity of known groups according to the 
benefit of treatment with TBS scale. Feasibility and burden of administration were 
also measured. Results: 25 couples of patients [mean (SD): 57.2 (16.0) years, 60% 
women] and relatives [63.0 (14.3) years, 44% women] were enrolled. The OAB-FIM 
was equivalent conceptually and linguistically to the original, remaining the six 
initial domains: activities, travel, concern, irritation, sleep and sex. Missing items 
was low (2.95%). Floor and ceiling effects varied, respectively, between 20%-28%, and 
0%-16%. The average time of completion was 5.2 (2.8) minutes. 24.0% needed some 
help to complete the questionnaire. The Rovinelli-Hambleton index ranked correctly 
all items in its domain, except for the item 10 which ranked in domains irrita-
tion and concern. α -Cronbach varied between 0.948-0.839. Correlations of OAB-FIM 
with ZARIT were high-to-moderate (0.407-0.753) and moderate-to-small with the 
OABq-SF (0.004-0.423). Relatives whose patients showed treatment benefit showed 
scores lower on the scale (lowest impact). ConClusions: A Spanish version of 
the OAB-FIM conceptually and linguistically equivalent to the original has been 
obtained. The questionnaire has shown good internal consistency, content validity 
and construct validity, together with feasibility in the Spanish culture.
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objeCtives: To develop and validate a patient-reported questionnaire assessing 
the fears and beliefs of patients suffering from rheumatoid arthritis (RA) or spon-
dyloarthritis (SpA), that could improve educational programs. Methods: Step 1: 
Qualitative research (individual patient interviews: 25 RA, 25 axial SpA [axSpA]). Step 
2: All fears and beliefs appearing in more than 10% of interviews rephrased as ques-
tions by an expert group including a patient-partner. Each question scored 0–10 (10= 
higher fears/stronger beliefs). Step 3: Preliminary questionnaire tested by cognitive 
debriefing (5 RA, 5 axSpA patients), and reproducibility through a test-retest procedure 
among 28 patients (13 RA, 15 axSpA). Step 4: Psychometric validation through a cross-
sectional study of 226 patients. Internal consistency assessed by Cronbach’s alpha, 
